Total Therapy 5

Title:  UARK 2008-02, TOTAL THERAPY 5 – A Phase II Trial for High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by applying Non-Host-Exhausting and Timely Dose- Reduced MEL-80+VRD-PACE Tandem Transplants with Interspeed MEL-20-VTD-PACE and alternating V-RD AND M-RD Maintenance 
Sponsor:    UAMS/ MIRT 
PI:  Saad Usmani, MD
Phase:  II 
Purpose:  This study has the following specific goals:

  • To find out if giving multi-agent chemotherapy in lower and more frequent doses to make the timely delivery of chemotherapy cycles possible, will result in fewer side effects, while still being effective
  • To find out if changing the way the drugs are given during the transplant phase will also result in fewer side effects, while still being effective
  • To find out if giving treatment between transplants (called “inter-transplant therapy”) will prevent the myeloma from regrowing between transplants 

Eligibility:    You are being asked to take part in this research study because you have high-risk multiple myeloma that requires treatment. About 90 research participants, male or female, age 18 or older, regardless of race or ethnicity, will take part in this study. 
Treatment:   The treatment on this study is divided into five phases:

  1. Induction chemotherapy and stem cell collection
  2. Transplant #1
  3. Inter-Transplants #1 and #2
  4. Transplant #2
  5. Maintenance therapy 

Contact:  Nathan Petty
E-mail: pettynathanm@uams.edu
Phone: 501-526-6990 ext. 2435